Gilead Sciences Surges to Top 54 Most Actively Traded Stocks with 11.98 Billion Shares Exchanged

On June 5, 2025, Gilead Sciences (GILD) saw a significant increase in trading volume, with a total of 11.98 billion shares exchanged, marking a 37.57% rise from the previous day. This surge placed Gilead among the top 54 most actively traded stocks for the day, with the stock price rising by 1.32%.

Gilead Sciences is at the forefront of developing innovative therapies to combat the HIV epidemic. The company is dedicated to delivering groundbreaking treatments to those in greatest need, showcasing its commitment to public health.

Gilead Sciences has been recognized for its strong buy rating by 18 analysts, with an additional 1 moderate buy and 9 hold ratings. The stock has been trading within a range of 95 to 120 over the past few months, reflecting its stability and investor confidence.

Gilead's portfolio includes key HIV/AIDS therapies such as Genvoya, Odefsey, Descovy, Biktarvy, and Truvada. The company's hepatitis C virus drugs, Harvoni and Epclusa, along with its HBV drug, further diversify its offerings. Additionally, Gilead has made significant strides in the oncology space with strategic collaborations and acquisitions, including the approval of Tecartus for the treatment of relapsed or refractory mantle cell lymphoma.

Gilead's lenacapavir, a long-acting HIV drug, has received FDA priority review following strong trial results. The company aims to double the number of U.S. PrEP users by 2035, demonstrating its commitment to expanding access to preventive treatments.

At the Global Life Sciences Conference, Gilead outlined a robust pipeline with a focus on virology, oncology, and immunology. The company highlighted both promising developments and competitive challenges, underscoring its strategic vision for growth and innovation.